查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1879277

缺铁性贫血治疗市场－全球产业规模、份额、趋势、机会和预测，按治疗类型、最终用户、地区和竞争格局划分，2020-2030年预测

Iron Deficiency Anemia Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy Type, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024年全球缺铁性贫血治疗市场规模为54.9亿美元，预计2030年将以6.70%的复合年增长率成长至81亿美元。缺铁性贫血（IDA）治疗主要包括药物干预，例如口服和静脉注射铁剂，旨在补充体内耗竭的铁储备，从而促进足够的血红蛋白合成，并缓解缺铁相关症状。全球缺铁性贫血盛行率的不断上升、公众和医疗界对早期诊断和有效治疗的认识不断提高，以及治疗製剂的进步，是推动全球市场扩张的主要因素。

市场概览
预测期 2026-2030
2024年市场规模 54.9亿美元
2030年市场规模 81亿美元
2025-2030年复合年增长率 6.7%
成长最快的细分市场 口服铁剂治疗
最大的市场 北美洲

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球缺铁性贫血治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依治疗类型（口服铁剂治疗、肠外铁剂治疗、红血球输注）
    • 依最终使用者（医院、诊所、家庭医疗保健）划分
    • 按地区
    • 按公司（2024 年）
  • 市场地图

第六章：北美缺铁性贫血治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第七章：欧洲缺铁性贫血治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区缺铁性贫血治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲缺铁性贫血治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿联酋
    • 南非

第十章：南美洲缺铁性贫血治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章：市场动态

  • 司机
  • 挑战

第十二章：市场趋势与发展

  • 併购（如有）
  • 产品发布（如有）
  • 最新进展

第十三章：全球缺铁性贫血治疗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商议价能力
  • 顾客的力量
  • 替代产品的威胁

第十五章：竞争格局

  • Daiichi Sankyo Company
  • Novartis AG
  • Rockwell Medical Inc
  • Iron4u Aps
  • AbbVie Inc
  • Sanofi
  • Disc Medicine Inc
  • Pfizer Inc
  • Akebia Therapeutics
  • Keros Therapeutics Inc

第十六章：策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 16192

The Global Iron Deficiency Anemia Therapy Market, valued at USD 5.49 Billion in 2024, is projected to experience a CAGR of 6.70% to reach USD 8.10 Billion by 2030. Iron Deficiency Anemia (IDA) Therapy involves pharmaceutical interventions, primarily oral and intravenous iron supplements, designed to replenish depleted iron stores, thereby enabling adequate hemoglobin synthesis and alleviating symptoms associated with iron deficiency. The global market's expansion is significantly propelled by the increasing worldwide prevalence of iron deficiency anemia, heightened public and medical awareness concerning early diagnosis and effective management, and advancements in therapeutic formulations.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 5.49 Billion
Market Size 2030USD 8.10 Billion
CAGR 2025-20306.7%
Fastest Growing SegmentOral Iron Therapy
Largest MarketNorth America

Key Market Drivers

The rising prevalence of iron deficiency anemia fundamentally drives market expansion, creating a substantial global demand for effective therapeutic interventions. This widespread nutritional deficiency necessitates consistent, accessible treatment, directly propelling the growth of pharmaceutical and supplementary solutions. For instance, according to the World Health Organization, in February 2025, an estimated 269 million children aged 6-59 months worldwide were affected by anemia. This large patient demographic ensures continuous requirement for diagnosis and subsequent treatment, underpinning the market's sustained growth.

Key Market Challenges

The considerable cost associated with advanced intravenous iron therapies presents a significant challenging factor, directly impeding the growth of the Global Iron Deficiency Anemia Therapy Market. This high cost often results in restrictive reimbursement policies from payers, who may prioritize less expensive, older-generation intravenous iron formulations through mechanisms such as step therapy requirements. Such policies compel patients to first attempt therapies that may be less effective or require more frequent administrations.

Key Market Trends

The emergence of nanomedicine in iron formulations represents a significant advancement, addressing challenges associated with conventional iron therapies such as bioavailability and side effects. These novel formulations, designed at the nanoscale, offer improved absorption kinetics and reduced gastrointestinal distress, enhancing patient adherence and therapeutic outcomes. For instance, in February 2023, the IHAT-GUT trial published in *EClinicalMedicine* demonstrated that a novel nano-iron supplement, iron hydroxide adipate tartrate (IHAT), showed non-inferiority compared to standard ferrous sulfate for iron deficiency correction and hemoglobin response in children aged 6-35 months, warranting further Phase III trials.

Key Market Players

  • Daiichi Sankyo Company
  • Novartis AG
  • Rockwell Medical Inc
  • Iron4u Aps
  • AbbVie Inc
  • Sanofi
  • Disc Medicine Inc
  • Pfizer Inc
  • Akebia Therapeutics
  • Keros Therapeutics Inc

Report Scope:

In this report, the Global Iron Deficiency Anemia Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Iron Deficiency Anemia Therapy Market, By Therapy Type:

  • Oral Iron Therapy
  • Parenteral Iron Therapy
  • Red Blood Cell Transfusion

Iron Deficiency Anemia Therapy Market, By End User:

  • Hospitals
  • Clinics
  • Home Healthcare

Iron Deficiency Anemia Therapy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Iron Deficiency Anemia Therapy Market.

Available Customizations:

Global Iron Deficiency Anemia Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Iron Deficiency Anemia Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy Type (Oral Iron Therapy, Parenteral Iron Therapy, Red Blood Cell Transfusion)
    • 5.2.2. By End User (Hospitals, Clinics, Home Healthcare)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Iron Deficiency Anemia Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Iron Deficiency Anemia Therapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapy Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Iron Deficiency Anemia Therapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapy Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Iron Deficiency Anemia Therapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapy Type
        • 6.3.3.2.2. By End User

7. Europe Iron Deficiency Anemia Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Iron Deficiency Anemia Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy Type
        • 7.3.1.2.2. By End User
    • 7.3.2. France Iron Deficiency Anemia Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy Type
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Iron Deficiency Anemia Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy Type
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Iron Deficiency Anemia Therapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapy Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Iron Deficiency Anemia Therapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapy Type
        • 7.3.5.2.2. By End User

8. Asia Pacific Iron Deficiency Anemia Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Iron Deficiency Anemia Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Iron Deficiency Anemia Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Iron Deficiency Anemia Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Iron Deficiency Anemia Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Iron Deficiency Anemia Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy Type
        • 8.3.5.2.2. By End User

9. Middle East & Africa Iron Deficiency Anemia Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Iron Deficiency Anemia Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy Type
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Iron Deficiency Anemia Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy Type
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Iron Deficiency Anemia Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy Type
        • 9.3.3.2.2. By End User

10. South America Iron Deficiency Anemia Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Iron Deficiency Anemia Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Iron Deficiency Anemia Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy Type
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Iron Deficiency Anemia Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Iron Deficiency Anemia Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Daiichi Sankyo Company
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Rockwell Medical Inc
  • 15.4. Iron4u Aps
  • 15.5. AbbVie Inc
  • 15.6. Sanofi
  • 15.7. Disc Medicine Inc
  • 15.8. Pfizer Inc
  • 15.9. Akebia Therapeutics
  • 15.10. Keros Therapeutics Inc

16. Strategic Recommendations

17. About Us & Disclaimer